Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | IL1B | P01584 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5206693 | 0.81 | MAOB (0.51) | L3MBTL1PTK2ALDH1A1HPGDKMT2A | |
| SCHEMBL13947117 | 0.81 | HCAR3 (0.56) | L3MBTL1PTK2ALDH1A1HPGDKMT2A | |
| Hydrochloric Acid SCHEMBL6441856 | 0.79 | MAOB (0.50) | L3MBTL1PTK2ALDH1A1HPGDKMT2A | |
| SCHEMBL10736213 | 0.78 | STK17A (0.51) | L3MBTL1PTK2ALDH1A1HPGDKMT2A | |
| SCHEMBL530600 | 0.77 | KDM4E (0.46) | MKNK1ALDH1A1KDM4EPOLBGAA | |
| SCHEMBL1570064 | 0.77 | KDM4E (0.46) | MKNK1ALDH1A1KDM4EPOLBGAA | |
| SCHEMBL7891213 | 0.77 | KDM4E (0.46) | MKNK1ALDH1A1KDM4EPOLBGAA | |
| SCHEMBL12832042 | 0.77 | RAB9A (0.52) | ALDH1A1HPGDKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL182559 | 0.77 | NPC1 (0.53) | ALDH1A1HPGDKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL24896377 | 0.77 | HCAR3 (0.59) | MKNK1L3MBTL1PTK2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | MKNK1 334/4885L3MBTL1 1437/4885PTK2 1254/4885 |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | MAPT, PSEN2, PSEN1 | MKNK1 593/4885L3MBTL1 2257/4885PTK2 1402/4885 |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | PDE3A, PDE5A, PDE2A | MKNK1 3590/4885L3MBTL1 4376/4885PTK2 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.